Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab Meeting Abstract
| Authors: | Passaro, A.; Yu, H. A.; Nguyen, D.; Lee, V. H. F.; Soo, R. A.; Kim, S. H.; Daga, H.; Tan, D. S. W.; Kim, S. W.; Juan Vidal, O. J.; Piotrowska, Z.; Keeton, E. K.; Liu, T.; Li, S.; Jones, J.; Ruiter, G. |
| Abstract Title: | Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S803 |
| End Page: | S804 |
| Language: | English |
| ACCESSION: | WOS:001326612901557 |
| DOI: | 10.1016/j.annonc.2024.08.1311 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1254MO -- Source: Wos |
